Capricor Therapeutics, Inc. (FRA:4LN2)
Germany · Delayed Price · Currency is EUR | Market Cap | 459.32M +95.8% |
| Revenue (ttm) | n/a |
| Net Income | -113.28M |
| EPS | -2.16 |
| Shares Out | n/a |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | n/a |
| Open | 8.05 |
| Previous Close | 7.54 |
| Day's Range | 8.05 - 8.06 |
| 52-Week Range | 2.58 - 30.10 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Nov 11, 2026 |
About Capricor Therapeutics
Capricor Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of transformative cell and exosome-based therapeutics for treating duchenne muscular dystrophy (DMD) and other diseases with unmet medical needs in the United States. Its lead product candidate is the Deramiocel, an allogeneic cardiosphere-derived cells, which is in phase 3 clinical trial for the treatment of DMD. The company also develops Exosome protein-based vaccine, which is in preclinical trial to treat SARS-CoV-2; StealthX Exosome Platform, and... [Read more]
News
Capricor Therapeutics, Inc. Stockholders with Significant Losses Should Contact Robbins LLP Before the Pending September 28, 2026 Lead Plaintiff Deadline
SAN DIEGO, Sept. 18, 2026 /PRNewswire/ -- Robbins LLP informs investors that a securities class action has been filed on behalf of all persons and entities that purchased or otherwise acquired Caprico...
Capricor Therapeutics to Present HOPE-3 and HOPE-3 Open-Label Extension Data at 2026 World Muscle Society Congress
– Late-Breaking Data to Include HOPE-3 Delayed-Start and Natural History Analyses Submitted in the Recent Major Amendment to the Deramiocel BLA – – PDUFA Target Action Date of November 22, 2026 – SAN ...
Kaplan Fox Advises Investors of Capricor Therapeutics, Inc. (CAPR) to Contact the Firm Before the Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - September 14, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
Capricor Therapeutics upgraded to Buy from Neutral at B. Riley
B. Riley analyst Madison El-Saadi upgraded Capricor Therapeutics (CAPR) to Buy from Neutral with a price target of $21, up from $5. The share setup is favorable into the November…
Kaplan Fox Encourages Capricor Therapeutics, Inc. (CAPR) Investors Who Suffered Losses to Seek a Leadership Role Before September 28, 2026
New York, New York--(Newsfile Corp. - September 11, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Com...
SHAREHOLDER REMINDER: Berger Montague Reminds Capricor Therapeutics, Inc. (CAPR) Investors of the September 28, 2026 Deadline
Philadelphia, Pennsylvania--(Newsfile Corp. - September 11, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR)...
Kaplan Fox Alerts Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to an Approaching Lead Plaintiff Deadline on September 28, 2026
NEW YORK, Sept. 11, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
LAWSUIT INVESTOR NOTICE: Investors who lost money with Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares should contact the Shareholders Foundation
SAN DIEGO--(BUSINESS WIRE)--The Shareholders Foundation, Inc. announced that a lawsuit was filed for certain investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) shares in the U.S. District Court f...
Capricor Therapeutics (NASDAQ:CAPR) Shares Fall 64% Following Clinical Data Disclosure -- Investors with Losses Notified to Contact BFA Law before September 28 Deadline
NEW YORK, Sept. 07, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CA...
Kaplan Fox Encourages Investors of Capricor Therapeutics, Inc. (CAPR) to Act Ahead of the Lead Plaintiff Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - September 4, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Comp...
Kaplan Fox Notifies Investors of Capricor Therapeutics, Inc. (NASDAQ: CAPR) of the Lead Plaintiff Deadline on September 28, 2026
NEW YORK, Sept. 04, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
Kaplan Fox Alerts Capricor Therapeutics, Inc. (CAPR) Investors to the Lead Plaintiff Deadline on September 28, 2026
New York, New York--(Newsfile Corp. - September 2, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Comp...
Kaplan Fox Urges Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (“Capricor” or the “Company”) (NASDAQ:...
$CAPR News: Capricor Therapeutics Sued for Securities Fraud Over Alleged Misrepresentations about its Clinical Data – Contact BFA Law by September 28 if You Lost Money
NEW YORK, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Leading securities law firm Bleichmar Fonti & Auld LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ:CAP...
Kaplan Fox Urges Capricor Therapeutics, Inc. (CAPR) Investors Seeking Recovery to Contact the Firm Before September 28, 2026
New York, New York--(Newsfile Corp. - September 1, 2026) - Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. ("Capricor" or the "Comp...
Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler analyst Edward Tenthoff upgraded Capricor Therapeutics (CAPR) to Overweight from Neutral with a price target of $25, up from $2. The FDA last week extended the action date…
Capricor Therapeutics upgraded to Overweight from Neutral at Piper Sandler
Piper Sandler upgraded Capricor Therapeutics (CAPR) to Overweight from Neutral with a $25 price target
Capricor Therapeutics, Inc. (CAPR) Securities Fraud: Contact Berger Montague To Discuss Your Rights
Philadelphia, Pennsylvania--(Newsfile Corp. - August 28, 2026) - National plaintiffs' law firm Berger Montague PC announces a class action lawsuit against Capricor Therapeutics, Inc. (NASDAQ: CAPR) ("...
Kaplan Fox Encourages Capricor Therapeutics, Inc. (NASDAQ: CAPR) Investors to Contact the Firm Before the Deadline on September 28, 2026 for a Leadership Role
Kaplan Fox & Kilsheimer LLP announces that a class action lawsuit has been filed against Capricor Therapeutics, Inc. (NASDAQ: CAPR) on behalf of investors.
SueWallSt Reminds Shareholders of a Lead Plaintiff Deadline of September 28, 2026 in Capricor Therapeutics, Inc. Lawsuit - CAPR
NEW YORK, Aug. 25, 2026 (GLOBE NEWSWIRE) -- SueWallSt notifies investors in Capricor Therapeutics, Inc. (NASDAQ: CAPR) that a class action has been filed on behalf of shareholders who purchased securi...
Capricor Therapeutics upgraded to Outperform from Perform at Oppenheimer
Oppenheimer upgraded Capricor Therapeutics (CAPR) to Outperform from Perform with a $54 price target following yesterday’s regulatory update and further color from a follow-up call with the CEO. The f...
Wainwright says Capricor’s regulatory risk still high after FDA PDUFA extension
H.C. Wainwright notes that Capricor Therapeutics (CAPR) announced that the FDA extended the PDUFA target action date for deramiocel from August 22 to November 22, following submission of a major…
US FDA extends review of Capricor's muscle disorder therapy by three months
Capricor Therapeutics said on Monday that the U.S. Food and Drug Administration had extended the review of its experimental cell therapy for Duchenne muscular dystrophy by three months.
Capricor says FDA extends action date for Deramiocel for amendment review
Capricor Therapeutics (CAPR) announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act target action date for its biologics license application Deramiocel, a...
Capricor Therapeutics jumps 18% to $7.42 as FDA reviews Deramiocel
09:32 EDT Capricor Therapeutics (CAPR) jumps 18% to $7.42 as FDA reviews Deramiocel